Meeting
2012 ASCO Annual Meeting
YOCAS yoga for musculoskeletal symptoms in breast cancer patients receiving aromatase inhibitors: A URCC CCOP randomized, controlled clinical trial.
Authors
Luke Joseph Peppone
University of Rochester Medical Center, Rochester, NY
Luke Joseph Peppone , Supriya Gupta Mohile , Michelle Christine Janelsins , Lisa Sprod , Jennifer S. Gewandter , Charles E. Heckler , Kavita Dayal Chandwani , Gary R. Morrow , Janet C. Ruzich , Benjamin Esparaz , Karen Michelle Mustian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT00397930
Citation
J Clin Oncol 30, 2012 (suppl; abstr 9028)
DOI
10.1200/jco.2012.30.15_suppl.9028
Abstract #
9028
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
First Author: Elizabeth Joyce
Poster
2020 ASCO Virtual Scientific Program
Breast Cancer Index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial.
First Author: Gerrit-Jan Liefers